Changes in plasma, erythrocyte, and platelet magnesium levels in normotensive and hypertensive obese subjects during oral glucose tolerance test

F. Corica, A. Allegra, R. Ientile, M. Buemi, A. Corsonello, S. Bonanzinga, S. Macaione, D. Ceruso

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

We evaluated the 75-g oral glucose tolerance test (OGTT)-induced modifications in glucose, insulin, and norepinephrine plasma concentrations, and in plasma, erythrocyte, and platelet magnesium levels in two groups of obese subjects (normotensive obese, NT-Ob, N = 19; hypertensive obese, HT- Ob, N = 15), and in a group of healthy control subjects (N = 12). During OGTT we detected a reduction in plasma magnesium concentrations and an increase in erythrocyte and platelet magnesium levels in the controls, whereas in both normotensive and hypertensive obese subjects, there was a reduction in plasma, erythrocyte, and platelet magnesium levels. Furthermore, no statistically significant difference was detected among the groups studied as regards Δ-plasma magnesium. On the other hand, Δ-erythrocyte magnesium and Δ-platelet magnesium were negative in the NT-Ob (Δ-erythrocyte magnesium: - 0.24 ± 0.08 mmol/L; Δ-platelet magnesium: -0.49 ± 0.09 μmol/108 cells) and HT-Ob (Δ-erythrocyte magnesium: -0.20 ± 0.10 mmol/L; Δ-platelet magnesium: -0.50 ± 0.11 μmol/108 cells) groups, and positive in control subjects (Δ-erythrocyte magnesium: 0.40 ± 0.08 μmol/L; Δ-platelet magnesium: 0.47 ± 0.09 mmol/108 cells). Finally, a direct correlation was found between Δ-norepinephrine and Δ-erythrocyte magnesium (r = 0.80, P <.01) in the control group, and a negative correlation was detected between Δ-norepinephrine and Δ-platelet magnesium (r = -0.58, P <.05) in the HT- Ob group. Our results seem to indicate that the insulin resistance status, the hyperglycemia, and the disregulation of the adrenergic system in obese subjects could be involved in the pathogenesis of the magnesium homeostasis impairment observed in the obese subjects.

Original languageEnglish
Pages (from-to)128-136
Number of pages9
JournalAmerican Journal of Hypertension
Volume12
Issue number2 I
DOIs
Publication statusPublished - 1999

Fingerprint

Glucose Tolerance Test
Magnesium
Blood Platelets
Erythrocytes
Norepinephrine
Control Groups
Hyperglycemia
Adrenergic Agents
Insulin Resistance

Keywords

  • Norepinephrine
  • Obesity
  • Oral glucose tolerance test
  • Platelet magnesium

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Changes in plasma, erythrocyte, and platelet magnesium levels in normotensive and hypertensive obese subjects during oral glucose tolerance test. / Corica, F.; Allegra, A.; Ientile, R.; Buemi, M.; Corsonello, A.; Bonanzinga, S.; Macaione, S.; Ceruso, D.

In: American Journal of Hypertension, Vol. 12, No. 2 I, 1999, p. 128-136.

Research output: Contribution to journalArticle

Corica, F. ; Allegra, A. ; Ientile, R. ; Buemi, M. ; Corsonello, A. ; Bonanzinga, S. ; Macaione, S. ; Ceruso, D. / Changes in plasma, erythrocyte, and platelet magnesium levels in normotensive and hypertensive obese subjects during oral glucose tolerance test. In: American Journal of Hypertension. 1999 ; Vol. 12, No. 2 I. pp. 128-136.
@article{f22e5cfc70ea441e8bdf9b3a8d0995e2,
title = "Changes in plasma, erythrocyte, and platelet magnesium levels in normotensive and hypertensive obese subjects during oral glucose tolerance test",
abstract = "We evaluated the 75-g oral glucose tolerance test (OGTT)-induced modifications in glucose, insulin, and norepinephrine plasma concentrations, and in plasma, erythrocyte, and platelet magnesium levels in two groups of obese subjects (normotensive obese, NT-Ob, N = 19; hypertensive obese, HT- Ob, N = 15), and in a group of healthy control subjects (N = 12). During OGTT we detected a reduction in plasma magnesium concentrations and an increase in erythrocyte and platelet magnesium levels in the controls, whereas in both normotensive and hypertensive obese subjects, there was a reduction in plasma, erythrocyte, and platelet magnesium levels. Furthermore, no statistically significant difference was detected among the groups studied as regards Δ-plasma magnesium. On the other hand, Δ-erythrocyte magnesium and Δ-platelet magnesium were negative in the NT-Ob (Δ-erythrocyte magnesium: - 0.24 ± 0.08 mmol/L; Δ-platelet magnesium: -0.49 ± 0.09 μmol/108 cells) and HT-Ob (Δ-erythrocyte magnesium: -0.20 ± 0.10 mmol/L; Δ-platelet magnesium: -0.50 ± 0.11 μmol/108 cells) groups, and positive in control subjects (Δ-erythrocyte magnesium: 0.40 ± 0.08 μmol/L; Δ-platelet magnesium: 0.47 ± 0.09 mmol/108 cells). Finally, a direct correlation was found between Δ-norepinephrine and Δ-erythrocyte magnesium (r = 0.80, P <.01) in the control group, and a negative correlation was detected between Δ-norepinephrine and Δ-platelet magnesium (r = -0.58, P <.05) in the HT- Ob group. Our results seem to indicate that the insulin resistance status, the hyperglycemia, and the disregulation of the adrenergic system in obese subjects could be involved in the pathogenesis of the magnesium homeostasis impairment observed in the obese subjects.",
keywords = "Norepinephrine, Obesity, Oral glucose tolerance test, Platelet magnesium",
author = "F. Corica and A. Allegra and R. Ientile and M. Buemi and A. Corsonello and S. Bonanzinga and S. Macaione and D. Ceruso",
year = "1999",
doi = "10.1016/S0895-7061(98)00174-5",
language = "English",
volume = "12",
pages = "128--136",
journal = "American Journal of Hypertension",
issn = "0895-7061",
publisher = "Oxford University Press",
number = "2 I",

}

TY - JOUR

T1 - Changes in plasma, erythrocyte, and platelet magnesium levels in normotensive and hypertensive obese subjects during oral glucose tolerance test

AU - Corica, F.

AU - Allegra, A.

AU - Ientile, R.

AU - Buemi, M.

AU - Corsonello, A.

AU - Bonanzinga, S.

AU - Macaione, S.

AU - Ceruso, D.

PY - 1999

Y1 - 1999

N2 - We evaluated the 75-g oral glucose tolerance test (OGTT)-induced modifications in glucose, insulin, and norepinephrine plasma concentrations, and in plasma, erythrocyte, and platelet magnesium levels in two groups of obese subjects (normotensive obese, NT-Ob, N = 19; hypertensive obese, HT- Ob, N = 15), and in a group of healthy control subjects (N = 12). During OGTT we detected a reduction in plasma magnesium concentrations and an increase in erythrocyte and platelet magnesium levels in the controls, whereas in both normotensive and hypertensive obese subjects, there was a reduction in plasma, erythrocyte, and platelet magnesium levels. Furthermore, no statistically significant difference was detected among the groups studied as regards Δ-plasma magnesium. On the other hand, Δ-erythrocyte magnesium and Δ-platelet magnesium were negative in the NT-Ob (Δ-erythrocyte magnesium: - 0.24 ± 0.08 mmol/L; Δ-platelet magnesium: -0.49 ± 0.09 μmol/108 cells) and HT-Ob (Δ-erythrocyte magnesium: -0.20 ± 0.10 mmol/L; Δ-platelet magnesium: -0.50 ± 0.11 μmol/108 cells) groups, and positive in control subjects (Δ-erythrocyte magnesium: 0.40 ± 0.08 μmol/L; Δ-platelet magnesium: 0.47 ± 0.09 mmol/108 cells). Finally, a direct correlation was found between Δ-norepinephrine and Δ-erythrocyte magnesium (r = 0.80, P <.01) in the control group, and a negative correlation was detected between Δ-norepinephrine and Δ-platelet magnesium (r = -0.58, P <.05) in the HT- Ob group. Our results seem to indicate that the insulin resistance status, the hyperglycemia, and the disregulation of the adrenergic system in obese subjects could be involved in the pathogenesis of the magnesium homeostasis impairment observed in the obese subjects.

AB - We evaluated the 75-g oral glucose tolerance test (OGTT)-induced modifications in glucose, insulin, and norepinephrine plasma concentrations, and in plasma, erythrocyte, and platelet magnesium levels in two groups of obese subjects (normotensive obese, NT-Ob, N = 19; hypertensive obese, HT- Ob, N = 15), and in a group of healthy control subjects (N = 12). During OGTT we detected a reduction in plasma magnesium concentrations and an increase in erythrocyte and platelet magnesium levels in the controls, whereas in both normotensive and hypertensive obese subjects, there was a reduction in plasma, erythrocyte, and platelet magnesium levels. Furthermore, no statistically significant difference was detected among the groups studied as regards Δ-plasma magnesium. On the other hand, Δ-erythrocyte magnesium and Δ-platelet magnesium were negative in the NT-Ob (Δ-erythrocyte magnesium: - 0.24 ± 0.08 mmol/L; Δ-platelet magnesium: -0.49 ± 0.09 μmol/108 cells) and HT-Ob (Δ-erythrocyte magnesium: -0.20 ± 0.10 mmol/L; Δ-platelet magnesium: -0.50 ± 0.11 μmol/108 cells) groups, and positive in control subjects (Δ-erythrocyte magnesium: 0.40 ± 0.08 μmol/L; Δ-platelet magnesium: 0.47 ± 0.09 mmol/108 cells). Finally, a direct correlation was found between Δ-norepinephrine and Δ-erythrocyte magnesium (r = 0.80, P <.01) in the control group, and a negative correlation was detected between Δ-norepinephrine and Δ-platelet magnesium (r = -0.58, P <.05) in the HT- Ob group. Our results seem to indicate that the insulin resistance status, the hyperglycemia, and the disregulation of the adrenergic system in obese subjects could be involved in the pathogenesis of the magnesium homeostasis impairment observed in the obese subjects.

KW - Norepinephrine

KW - Obesity

KW - Oral glucose tolerance test

KW - Platelet magnesium

UR - http://www.scopus.com/inward/record.url?scp=0033030551&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033030551&partnerID=8YFLogxK

U2 - 10.1016/S0895-7061(98)00174-5

DO - 10.1016/S0895-7061(98)00174-5

M3 - Article

C2 - 10090339

AN - SCOPUS:0033030551

VL - 12

SP - 128

EP - 136

JO - American Journal of Hypertension

JF - American Journal of Hypertension

SN - 0895-7061

IS - 2 I

ER -